Previous 10 | Next 10 |
Integra LifeSciences ( NASDAQ: IART ) sees its Q4 2022 adjusted EPS coming in between $0.92 and $0.96 per share. That compares to $0.84 for the same period in 2021. For full-year 2022, adjusted EPS is expected to be $3.34 to $3.38 . In 2021, m the figure was $3.18. Earlier...
Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Higher interest rates created a difficult year for ...
Medical device company Integra LifeSciences ( NASDAQ: IART ) on Tuesday tightened its previously provided guidance for Q4 revenue to a range of $397M to $398M. The company anticipated that its Q4 adj. EPS would be above the high end of its previous outlook of $0.87 to $0.91. ...
Fourth Quarter 2022 Fourth quarter 2022 revenue is expected to be in a range of $397 million to $398 million, representing a decrease of approximately 2% on a reported basis and an increase of approximately 3% on an organic basis compared to 2021. Fourth quarter 2022 adjusted ea...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...
PRINCETON, N.J., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Jan De Witte, president and chief executive officer will present at the 41st Annual J.P. Morgan Healthcare conference ...
PRINCETON, N.J., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of Surgical Innovation Associates (SIA). “This acquisition is...
Acquisition will add distinct new product solution for plastic and reconstructive surgery to address clinical needs and improve patient outcomes Deploys capital to support strong profitable growth and greater returns for our shareholders ...
Summary Having suffered through a sharp decline in earnings multiples, small cap growth stocks held up well in a volatile quarter marked by a sharp upward ratcheting of interest rates. The Strategy underperformed its benchmark, primarily due to weakness among health care holdings ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
21.25%Change Percent:
Integra LifeSciences Holdings Corporation Company Name:
IART Stock Symbol:
NASDAQ Market:
2024-07-29 18:00:04 ET Ryan Zimmerman from BTIG issued a price target of $22.00 for IART on 2024-07-29 16:12:00. The adjusted price target was set to $22.00. At the time of the announcement, IART was trading at $25.42. The overall price target consensus is at $51.17 with...
2024-07-29 17:15:01 ET BTIG analyst issues SELL recommendation for IART on July 29, 2024 04:12PM ET. IART was trading at $25.42 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 2 - Hold, 1 - Sell ...
2024-07-29 12:23:00 ET Shares of Integra Lifesciences (NASDAQ: IART) were sinking 15.5% as of 11 a.m. ET on Monday. The decline came after the medical technology company announced its second-quarter results before the market opened. Integra reported Q2 revenue of $418.2 million,...